Literature DB >> 26403349

Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.

Oliver Grottke, Markus Honickel, Joanne van Ryn, Hugo ten Cate, Rolf Rossaint, Henri M Spronk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26403349     DOI： 10.1016/j.jacc.2015.07.051

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  11 in total

1.  Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.

Authors:  Oliver Grottke; Till Braunschweig; Rolf Rossaint; Necib Akman; Janet M Leeds; Pamela B Conley; Markus Honickel
Journal:  Br J Anaesth       Date:  2019-06-13       Impact factor: 9.166

Review 2.  Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Authors:  Steen Husted; Freek W A Verheugt; Willemijn J Comuth
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

3.  Pharmacology: Dabigatran specific antidote.

Authors:  A Curto
Journal:  Br Dent J       Date:  2016-03-25       Impact factor: 1.626

Review 4.  [Management of hemorrhage in patients treated with direct oral anticoagulants].

Authors:  O Grottke; H Lier; S Hofer
Journal:  Anaesthesist       Date:  2017-09       Impact factor: 1.041

Review 5.  Idarucizumab: First Global Approval.

Authors:  Celeste B Burness
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 6.  Direct Oral Anticoagulants in Emergency Trauma Admissions.

Authors:  Marc Maegele; Oliver Grottke; Herbert Schöchl; Oliver A Sakowitz; Michael Spannagl; Jürgen Koscielny
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594

Review 7.  The Reversal of Direct Oral Anticoagulants in Animal Models.

Authors:  Markus Honickel; Necib Akman; Oliver Grottke
Journal:  Shock       Date:  2017-08       Impact factor: 3.454

8.  Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.

Authors:  Oliver Grottke; Joanne van Ryn; Christian Zentai; Guanfa Gan; Markus Honickel; Rolf Rossaint; Hugo Ten Cate; Henri M H Spronk
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

Review 9.  Management of bleeding in patients treated with direct oral anticoagulants.

Authors:  Marcel Levi
Journal:  Crit Care       Date:  2016-08-20       Impact factor: 9.097

Review 10.  Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Authors:  Oliver Grottke; James Aisenberg; Richard Bernstein; Patrick Goldstein; Menno V Huisman; Dara G Jamieson; Jerrold H Levy; Charles V Pollack; Alex C Spyropoulos; Thorsten Steiner; Gregory J Del Zoppo; John Eikelboom
Journal:  Crit Care       Date:  2016-04-28       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.